Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales

被引：0
作者：
Cardot Martin Emilie
Colombier Marie Alice
Gougeon Marine
Eric Farfour
Annabelle Pourbaix
Laurent Dortet
Limousin Lucie
Vasse Marc
机构：
[1] Hôpital Foch,Service de Biologie Clinique
[2] Hôpital Foch,Service de Médecine Interne Et Infectiologie Transversale
[3] CNR Résistance Aux Antibiotiques,undefined
[4] CHU Bicêtre,undefined
[5] UMR-S INSERM U1176,undefined
来源：
European Journal of Clinical Microbiology & Infectious Diseases | 2024年 / 43卷
关键词：
Enterobacterales; Carbapenemase; Aztreonam-avibactam; Strip;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The combination of ceftazidime-avibactam (CAZ-AVI) and aztreonam (ATM) is used to treat MBL-producing Enterobacterales-related infections. The new combination aztreonam-avibactam (AZA) is currently in development. We compared results obtained with the new MIC test strip (MTS) AZA (Liofilchem) with broth microdilution method (BMD) on 41 MBL-producing Enterobacterales from 41 clinical samples. The MTS AZA was also compared to combination testing method using CAZ-AVI and ATM strips. Compared to BMD, categorical agreement (CA) was 100%. Compared with combination testing method, CA was 97.6%. The MTS AZA can be used to determine MICs levels of AZA or CAZ-AVI/ATM combinations.
引用
收藏
页码：777 / 784
页数：7
相关论文
共 108 条
  • [1] Bonomo RA(2018)Carbapenemase-producing organisms: a global scourge Clin Infect Dis Off Publ Infect Dis Soc Am 3 1290-1297
  • [2] Burd EM(2017)The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace J Infect Dis 15 S28-36
  • [3] Conly J(2022)NDM-35-producing ST167 Escherichia coli highly resistant to β-lactams including cefiderocol Antimicrob Agents Chemother. 16 0031122-1878
  • [4] Limbago BM(2022)Last resort beta-lactam antibiotics for treatment of New-Delhi metallo-beta-lactamase producing Enterobacterales and other difficult-to-treat resistance in gram-negative bacteria: a real-life study Front Cell Infect Microbiol 12 1048633-354
  • [5] Poirel L(2021)Efficacy of Ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase-producing Enterobacterales Clin Infect Dis Off Publ Infect Dis Soc Am 1 1871-19
  • [6] Segre JA(2021)The revival of aztreonam in combination with avibactam against metallo-β-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases Antibiot Basel Switz 20 1012-2626
  • [7] Logan LK(2017)Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens Diagn Microbiol Infect Dis 88 352-e1720
  • [8] Weinstein RA(2019)Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-β-lactamase-producing gram-negative bacteria Antimicrob Agents Chemother 63 e00010-1651
  • [9] Poirel L(2023)Case report: continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales Front Med 10 1224922-1428
  • [10] Ortiz de la Rosa JM(2015)Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam J Antimicrob Chemother 70 2618-e517
12345678910